Omar Rafael Alemán

Dr. Omar Rafael Alemán

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2025 in Neuro-Oncology Advances
Verified
Journal Article
Open access
OAOmar Rafael Alemán
Omar Rafael Alemán
JQJuan Carlos Quintero
Juan Carlos Quintero
ICIgnacio Camacho-Arroyo
Ignacio Camacho-Arroyo
Glioblastoma (GB) is the most aggressive and frequent tumor in the central nervous system and, in humans, represents the worst prognosis for cancer. GB develops a very complex microenvironment, recruiting and interacting with a variety of cells and soluble factors, including immune cells, cytokines, and sex hormones, that contribute to GB survival and progression. Recent evidence has shown a crosstalk between cytokine and sex hormone signaling in GB. This communication could provide GB resistance to treatments and malignancy. Then, how GB orchestrates this communication is a matter of interest. For instance, a critical interaction between tumor necrosis factor-beta (TGF-β) and estrogen receptor signaling has been reported in regulating epithelial-mesenchymal transition, an essential step in GB progression. Furthermore, an inhibition of TGF-β signaling by androgen receptor has been reported to promote GB tumorigenesis in men. Conversely, it has been described that cytokines regulate steroid hormone production in different organs, and this mechanism could be involved in GB development and progression. All these data suggest an intercommunication between the immune and endocrine systems in the tumor microenvironment. Thus, in this review, we focus on explaining the knowledge about this critical intercommunication system and its implication in GB progression.

24 December 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
ZVZitlal-Lin Victoria-Avila
Zitlal-Lin Victoria-Avila
EMElba Reyes Maldonado
Elba Reyes Maldonado
MDMaria Lilia Dominguez-Lopez
Maria Lilia Dominguez-Lopez
JVJorge Vela-Ojeda
Jorge Vela-Ojeda
ALAranza Lozada-Ruiz
Aranza Lozada-Ruiz
RLRuth Angélica Lezama
Ruth Angélica Lezama
Background: Chronic inflammation and the development of cancer are closely linked, with components that comprise the tumour microenvironment—including proinflammatory cytokines—exerting essential tumourigenic effects. These proinflammatory cytokines include IL-1β, which has been reported to be overexpressed in several cancers and shown to activate several signalling pathways. These pathways may involve kinases such as AKT (serine/threonine kinase) and Src (Proto-oncogene tyrosine-protein kinase), and have a broad capacity to activate nuclear factors, including NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells), which can regulate the transcription of genes encoding proteins such as cIAP1 (Cellular Inhibitor of Apoptosis Protein 1), Bcl-2 (B-cell lymphoma 2), and cyclin D1, thereby regulating processes like apoptosis and cell cycle inhibition. Objectives: The aim of this study was to investigate the role of IL-1β (Interleukin-1 beta) in regulating cell death and proliferation in RS4:11 leukaemic lymphoblasts via the PI3K (Phosphoinositide 3-kinase)/AKT/Src/NF-κB pathway using an in vitro experimental approach. Methods: We employed flow cytometry to determine the expression levels and phosphorylation status of various proteins; proliferation was assessed using the CCK-8 kit, and apoptosis was evaluated with the Annexin V kit. Results: Our findings indicate that the IL-1β-activated signalling pathway modulates these cellular processes in leukaemic lymphoblasts. Conclusions: We therefore conclude that IL-1β exerts significant effects on cell death and proliferation in leukaemic lymphoblasts through the PI3K/AKT/NF-κB pathway, with the study’s findings indicating that an inflammatory environment may promote such lymphoblasts to acquire neoplastic characteristics. As such, the proteins involved in the effects evaluated in this work could be considered as potential therapeutic targets for the treatment of Acute Lymphoblastic Leukaemia (ALL).

27 May 2026 in Clinical Immunology Communications
Verified
Journal Article
Open access
NNNathalia Naranjo-Pinto
Nathalia Naranjo-Pinto
OAOmar Rafael Alemán
Omar Rafael Alemán
CRCARLOS ROSALES
CARLOS ROSALES

24 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ZVZitlal-Lin Victoria-Avila
Zitlal-Lin Victoria-Avila
EMElba Reyes Maldonado
Elba Reyes Maldonado
MDMaria Lilia Dominguez-Lopez
Maria Lilia Dominguez-Lopez
JVJorge Vela-Ojeda
Jorge Vela-Ojeda
ARAranza Lozada Ruiz
Aranza Lozada Ruiz
RLRuth Angélica Lezama
Ruth Angélica Lezama
Chronic inflammation and the development of cancer are closely linked, with components that comprise the tumour microenvironment—including proinflammatory cytokines—exerting essential tumourigenic effects. These proinflammatory cytokines include IL-1β, which has been reported to be overexpressed in several cancers and shown to activate several signalling pathways. These pathways may involve kinases such as AKT and Src, and have a broad capacity to activate nuclear factors, including NF-κB, which can regulate the transcription of genes encoding proteins such as cIAP1, Bcl-2, and cyclin D, thereby regulating processes like apoptosis and cell cycle inhibition. The objective of this study was to investigate the role of IL-1β in regulating cell death and proliferation in leukaemic lymphoblasts via the PI3K/AKT/NF-κB pathway. We employed flow cytometry to determine the expression levels and phosphorylation status of various proteins, proliferation was assessed using the CCK-8 kit, and apoptosis was evaluated with the Annexin V kit. Our findings indicate that the signalling pathway activated by IL-1β modulates these cellular processes in leukaemic lymphoblasts. We therefore conclude that IL-1β exerts significant effects on cell death and proliferation in leukaemic lymphoblasts through the PI3K/AKT/NF-κB pathway, with the study’s findings indicating that an inflammatory environment may promote such lymphoblasts to acquire neoplastic characteristics. As such, the proteins involved in the effects evaluated in this work could be considered as potential therapeutic targets for the treatment of Acute Lymphoblastic Leukaemia (ALL).